Mosunetuzumab

CHEMBL4297788 Phase 4 승인됨 Antibody

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

This bispecific antibody simultaneously binds to CD20 on B-cell lymphoma cells and CD3 on T cells, forcing the immune system's killer T cells into direct contact with cancer cells to destroy them. It offers a fixed-duration treatment option for patients with relapsed or refractory follicular lymphoma.

치료 영역

Immunology Oncology Lymphoma

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

자주 묻는 질문

This bispecific antibody simultaneously binds to CD20 on B-cell lymphoma cells and CD3 on T cells, forcing the immune system's killer T cells into direct contact with cancer cells to destroy them. It offers a fixed-duration treatment option for patients with relapsed or refractory follicular lymphoma.

Yes, Mosunetuzumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4297788. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-08-20.

PillFYI

환자 친화적 정보를 찾고 계신가요?

Mosunetuzumab PillFYI에서

핵심 데이터

동의어: 2

외부 링크

ChEMBL CHEMBL4297788

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

의학적 면책조항

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.